RASP Stock Overview
A leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Actavia Life Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.004 |
| 52 Week High | US$0.039 |
| 52 Week Low | US$0.0016 |
| Beta | -64.87 |
| 1 Month Change | 0% |
| 3 Month Change | -87.69% |
| 1 Year Change | -48.05% |
| 3 Year Change | -86.67% |
| 5 Year Change | n/a |
| Change since IPO | -99.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| RASP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.2% | 0.7% |
| 1Y | -48.1% | -7.0% | 23.0% |
Return vs Industry: RASP underperformed the US Biotechs industry which returned 27.9% over the past year.
Return vs Market: RASP underperformed the US Market which returned 38.9% over the past year.
Price Volatility
| RASP volatility | |
|---|---|
| RASP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: RASP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RASP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 1 | n/a | www.rasna.com |
Actavia Life Sciences, Inc., a leukemia-focused biotechnology company, engages in developing therapeutics for the treatment of acute myeloid leukemia (AML) and other forms of leukemia and lymphoma. It is developing RASP-201, a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase, a pathway that blocks differentiation and confers a poor prognosis to AML; and RASP-301, an NCE for NPM1, currently at the pre-clinical stage to treat refractory AML with reduced toxicity. The company was formerly known as Rasna Therapeutics, Inc. and changed its name to Actavia Life Sciences, Inc. in October 2023.
Actavia Life Sciences, Inc. Fundamentals Summary
| RASP fundamental statistics | |
|---|---|
| Market cap | US$3.09m |
| Earnings (TTM) | -US$406.65k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.6x
P/E RatioIs RASP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RASP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$406.65k |
| Earnings | -US$406.65k |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00053 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -13.9% |
How did RASP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/19 16:05 |
| End of Day Share Price | 2024/07/22 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Actavia Life Sciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|